Tardive Dyskinesia

Sialorrhea is a common symptom in patients with neurological conditions such as Parkinson’s disease, ALS, cerebral palsy, or in patients who have experienced a stroke.

Trials of valbenazine for TD do not find that the treatment adds to cardiovascular disease risks associated with schizophrenia or the cardiovascular complications of antipsychotics.

AIMS scores can vary based on the clinician and therefore action plans may differ.

The risks of vitamin E treatment seemed to outweigh the benefits in this particular case.

One-fifth of patients with TD recently surveyed reported they had no clinical support.

Using realistic diagnostic criteria will increase prevention of tardive dyskinesia.

Could valbenazine or extract of Ginkgo biloba be the next therapy to come down the pipeline for the antipsychotic-induced condition?

A noninvasive dyskinesia treatment may stem from a Parkinson's disease treatment.

The study that linked parkinsonism asymmetry to the severity of psychopathology is the first of its kind to examine the relationship.

Some of the non-modifiable risk factors found were determined to be patient-related — such as older age, female sex, and white or African descent.

The tablet is a drug formulation of both immediate and extended release amantadine that provides once-daily therapy for adult patients.

While withdrawal of anticholinergic drugs has been investigated in the past to improve TD symptoms, evidence is weak for arguments in favor and against the drug class for TD.

There is some evidence that taking branched chain neutral amino acids may help TD.

A review of clinical trials has shown that GPi and STN targets can be successful in DBS, but all options should be considered based on the needs of the patient.

Major mutations in the LRRK2 gene are the greatest contributor to PD. They are present in 1% to 2% of the people with PD worldwide.

Twelve months after the implantation of a DBS device, the average tic severity for patients improved by 45%.

Neuropsychiatric Inventory scores were improved by an average of 8.5 points with NBM DBS compared to sham stimulation.

Benitec Biopharma's BB-301 is an investigative ddRNAi therapy for oculopharyngeal muscular dystrophy.

Exercise for patients with PD has been shown to be effective, and for those in the early stages, high-intensity exercise can be beneficial.

Brain-derived neurotrophic factor, interleukin 6, and S100-beta concentration levels were consistent in tested TD patients.

In 2 different dose groups, patients reported gradual decreases in AIMS scores over 42 weeks.

Researchers gauged 3 pooled study results to consider the safety and tolerability of marketed valbenazine for TD.

Until recently, researchers were able to measure only the total concentrations of alpha and beta isomers instead of quantifying each of the 4 isomers.

"The frequency of causing tardive dyskinesia is lesser, but it’s not zero."